Skip navigation

 Login or Register | Member Centre

Posted AT 8:13 AM EST on 28/07/08

Sanofi-Aventis to buy Acambis for $551-million

The Associated Press

PARIS — Sanofi-Aventis SA said its planned £276-million ($551-million U.S.) acquisition of Acambis Plc will bolster its leading position in the vaccine market and strengthen its development pipeline. The deal, expected to close by the end of September, would add Acambis' key smallpox vaccine ACAM2000 to the existing portfolio of Sanofi Pasteur, the vaccines business of Sanofi-Aventis.

The full text of this article has 224 words.

To continue reading this article, you will need to purchase this article.

Already have a member account? Login now

Pay-Per-View Offers To read the complete article, select one of the following options

Purchasing from globeandmail.com is quick and secure.

Single Article: $4.95

4-pack: $17.95

Back to top